Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.38 -7.4%	$1.36	$0.77 ▼ $2.63	$123.18M	1.05	367,737 shs	795,076 shs
GOSS Gossamer Bio	$2.00 -2.0%	$1.41	$0.66 ▼ $2.18	$463.70M	1.95	2.78 million shs	2.69 million shs
ITOS iTeos Therapeutics	$10.09 -0.5%	$10.05	$4.80 ▼ $18.13	$388.10M	1.49	1.44 million shs	1.54 million shs
SVRA Savara	$2.59	$2.32	$1.89 ▼ $4.70	$447.65M	0.4	994,048 shs	689,345 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	-7.38%	-4.17%	-0.72%	+21.05%	-36.11%
GOSS Gossamer Bio	-1.96%	+8.70%	+65.29%	+69.49%	+121.41%
ITOS iTeos Therapeutics	-0.49%	-0.79%	-0.69%	+29.86%	-42.64%
SVRA Savara	0.00%	+0.39%	+23.33%	-23.82%	-43.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDL Cardiol Therapeutics	1.9329 of 5 stars	3.7	4.0	0.0	0.0	0.0	0.6
GOSS Gossamer Bio	3.9032 of 5 stars	3.5	1.0	4.7	3.8	1.7	0.0
ITOS iTeos Therapeutics	2.9201 of 5 stars	4.1	2.0	0.0	1.0	3.3	0.6
SVRA Savara	1.4606 of 5 stars	3.3	0.0	0.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	479.71% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	312.50% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.64	55.03% Upside
SVRA Savara	2.60	Moderate Buy	$5.60	116.22% Upside

Current Analyst Ratings Breakdown

Latest CRDL, ITOS, SVRA, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $10.50
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
GOSS Gossamer Bio	$114.70M	3.96	N/A	N/A	$0.13 per share	15.38
ITOS iTeos Therapeutics	$35M	11.03	N/A	N/A	$16.16 per share	0.62
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	8/11/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.48	N/A	N/A	N/A	N/A	-65.88%	-52.35%	8/11/2025 (Estimated)

Latest CRDL, ITOS, SVRA, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ITOS iTeos Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/11/2025	Q1 2025	SVRA Savara	-$0.12	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	0.01	3.26	3.26
GOSS Gossamer Bio	6.70	5.71	5.71
ITOS iTeos Therapeutics	N/A	14.13	14.13
SVRA Savara	0.20	14.91	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
GOSS Gossamer Bio	81.23%
ITOS iTeos Therapeutics	97.16%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
GOSS Gossamer Bio	6.70%
ITOS iTeos Therapeutics	12.50%
SVRA Savara	5.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	82.68 million	78.31 million	Not Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
SVRA Savara	20	172.84 million	163.63 million	Optionable

CRDL, ITOS, SVRA, and GOSS Headlines

Recent News About These Companies

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating

August 1 at 3:51 AM | msn.com

Savara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 25, 2025 | americanbankingnews.com

Savara: Repairing The Molbreevi aPAP Opportunity After RTF

July 22, 2025 | seekingalpha.com

Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

July 20, 2025 | marketbeat.com

Savara Announces New Employment Inducement Grant

July 18, 2025 | businesswire.com

Emerald Advisers LLC Raises Position in Savara Inc. (NASDAQ:SVRA)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Purchases 638,568 Shares of Savara Inc. (NASDAQ:SVRA)

July 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 6, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 27, 2025 | prnewswire.com

Savara Independent Director Acquires 177% More Stock

June 25, 2025 | finance.yahoo.com

Richard J. Hawkins Purchases 48,225 Shares of Savara Inc. (NASDAQ:SVRA) Stock

June 24, 2025 | insidertrades.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 16, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 13, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 12, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 11, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 9, 2025 | accessnewswire.comA

savara elects board members and approves proposals at annual meeting

June 8, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split

CRDL, ITOS, SVRA, and GOSS Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.38 -0.11 (-7.38%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.40 +0.02 (+1.45%)

As of 08/1/2025 07:59 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Gossamer Bio NASDAQ:GOSS

$2.00 -0.04 (-1.96%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/1/2025 07:07 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.09 -0.05 (-0.49%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.10 +0.01 (+0.05%)

As of 08/1/2025 04:04 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Savara NASDAQ:SVRA

$2.59 0.00 (0.00%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.04 (-1.74%)

As of 08/1/2025 07:56 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time